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جهد األكسدة والربوتني التفاعلي )ج( يف مرضى 
احلوادث الوعائية الدماغية ) السكتة االقفارية ( 
تأثري خالصة اجلنكوبالوبا
عماد ذنون، حلمي عبد اجلبار، �سياء طه
ال�سكتة االقفارية بقيا�س م�ستوى  التاأكد من وجود عالمات جهد االأك�سدة واال�ستجابة االلتهابية يف م�سل دم مر�سى  الهدف:  امللخ�ص: 
املالونديليهايد وحالة م�سادات االأك�سدة الكلّية والربوتني التفاعلي عايل احل�سا�سية )ج( يف م�سل دم املر�سى يف املرحلة املبكرة التالية 
لل�سكتة االقفارية وحتديد دور العالج بخال�سة اجلنكوبالوبا يف ت�سحيح عالمات جهد االأك�سدة واال�ستجابة االلتهابية. الطريقة: اأجريت 
الدرا�سة واحداً وثالثني مري�سا بال�سكتة االقفارية وثالثني  ابن �سينا يف مدينة املو�سل بالعراق. �سّمت هذه  الدرا�سة يف م�ست�سفى  هذه 
�سخ�سا من االأ�سحاء كمجموعة �سابطة. مت تق�سيم املر�سى اإىل جمموعتني: املجموعة االأوىل )15 مري�سا( مّت عالجهم بالطريقة التقليدية، 
واملجموعة الثانية )16 مري�سا( عوجلوا بالطريقة التقليدية اإ�سافة اإىل اجلنكوبالوبا ) 1500 ملغم/ يوميا( ملده �سهر. مّت قيا�س م�ستوى 
ال�سابطة  التفاعلي عايل احل�سا�سية )ج( من عينات دم املر�سى واملجموعة  والربوتني  الكلّية  االأك�سدة  املالونديليهايد وحالة م�سادات 
قبل العالج وبعده. النتائج . هناك زيادة معتّدة يف م�ستوى املالونديليهايد والربوتني التفاعلي عايل احل�سا�سية )ج( عند املر�سى مقارنة 
اأظهرت املجموعة االأوىل  الكلّية يف املر�سى. كما  ال�سابطة )P ≤0.001(، وانخفا�سا معنّدا يف م�ستوى م�سادات االأك�سدة  باملجموعة 
والثانية من املر�سى انخفا�سا معتّدا يف م�ستوى املالونديليهايد والربوتني التفاعلي عايل احل�سا�سية )ج(، مع ارتفاع معتّد يف م�ستوى 
حالة م�سادات االأك�سدة الكلّية باملقارنة مع م�ستويات ما قبل العالج. مل يكن هنالك اختالفا معتّدا يف م�ستوى املالونديايهايد يف م�سل 
الدم بني مر�سى املجموعة االأوىل والثانية بينما كان هناك ارتفاعا معتّدا يف حالة م�سادات االأك�سدة الكلّية وانخفا�سا معتّدا يف م�ستوى 
مع  اأك�سدة  احلادة جهد  االقفارية  ال�سكتة  ُي�ساحب  اخلال�صة:  الثانية.  املجموعة  )ج( يف مر�سى  نوع  احل�سا�سية  علي  التفاعلي  الربوتني 
ا�ستجابة التهابية يف الفرتة املبكرة التالية للحالة االقفارية،، واجلنكوبالوبا كان له دور فعال يف تقليل �رضر جهد االأك�سدة واال�ستجابة 
االلتهابية. 
مفتاح الكلمات: حادثة وعائية دماغية، الربوتني التفاعلي )ج(، اجلنكوبالوبا، حالة اقفارية، ،�سكتة، مالوندليهايد، جهد االأك�سدة ،حالة م�سادات 
االأك�سدة، العراق.
abstract: Objectives: This study aimed to investigate the presence of oxidative stress and inflammation in 
ischaemic stroke patients by measuring malondialdehyde (MDA), total antioxidant status (TAS), and highly-
sensitivity C-reactive protein (hsCRP) in the early post-ischaemic period, and to determine the role of Ginkgo biloba 
therapy in correcting the markers of oxidative stress and inflammation. Methods: This study was conducted at Ibn 
Seena Hospital, Mosul City, Iraq and included 31 cerebrovascular accident (CVA) patients and 30 healthy controls. 
Ischaemic stroke patients were divided into two groups: group I (n = 15) received conventional therapy; group II 
(n = 16) received conventional therapy with G. biloba (1500 mg/day) for 30 days. Blood samples were obtained 
from patients and controls before treatment and assays done of serum levels of MDA, TAS, and hsCRP. For CVA 
patients, a post-treatment blood sample was taken and the same parameters reassessed. Results: Compared with 
the controls, patients’ serum levels of MDA, and hsCRP were significantly higher (P ≤0.001) and TAS significantly 
lower. Group I and II patients reported a significant reduction in serum levels of MDA and hsCRP and a significant 
increase in serum levels of TAS, in comparison with pre-treatment levels. There was no significant difference (P = 
0.19) in serum MDA levels between groups I and II, whereas, serum TAS levels were significantly higher (P ≤0.01) 
and hsCRP significantly lower (P ≤0.01) in group II. Conclusion: Acute stroke is associated with oxidative stress 
and inflammatory response in the early period. G. biloba plays a potential role in reducing oxidative damage and 
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Stroke, or cerebrovascular accident (CVA), is the third leading cause of death after cardiovascular diseases and cancer.1 
In fact, it is the second-leading cause of mortality 
and disease among adults over 60 years of age 
worldwide.2 Approximately 80% of strokes are 
ischaemic in origin, since they result either from 
thrombus in situ or an embolism of distant origin.3 
Cerebral ischaemia initiates a cascade of cellular 
and molecular events that lead to brain damage, with 
one such event being post-ischaemic inflammation.4 
Focal cerebral ischaemia is associated with a local 
inflammatory reaction that contributes to tissue 
damage.5 Microglial cells in particular become 
activated and provoke tissue injury by releasing 
pro-inflammatory mediators and reactive oxygen 
species (ROS).6,7 When oxygen supply is limited 
during ischaemia, a calcium influx may activate 
phospholipase C, which results in a breakdown of 
membrane phospholipids, or may convert xanthine 
dehydrogenase to xanthine oxidase in the cerebral 
blood vessels leading to the formation of superoxide 
radicals and hydrogen peroxide.8 
ROS causes oxidative damage that may affect 
lipids, proteins, nucleic acids and other molecules. 
Quantification of lipid peroxidation end products 
is considered to be a measure of whole-body 
oxidative damage. Serum malondialdehyde (MDA), 
a marker of lipid peroxidation, is the most abundant 
aldehyde generated by the attack of free radicals on 
polyunsaturated fatty acids of cell membranes; its 
measurement provides information of oxidative 
injury in vivo.9 The impact of free radicals may 
also be obtained by comparisons of antioxidant 
concentrations, because serious damage by free 
radicals implies insufficiency of the body’s multilevel 
defence systems against radicals.10Measurement of 
the total antioxidant capacity (TAC) of biological 
fluids, however, is regarded as more physiologically 
representative in certain settings than individual 
antioxidants, and is believed to be a useful measure 
of how much the antioxidants present can protect 
against oxidative damage to membranes and other 
cellular components.11
C-reactive protein (CRP) has been the most 
extensively studied marker of inflammation. It is a 
novel plasma marker of atherothrombotic disease.12 
C-reactive protein (CRP) is produced not only 
by the liver but also in atherosclerotic lesions by 
vascular smooth muscle cells and macrophages in 
response to stimulation by the ‘pro-inflammatory’ 
cytokine interleukin-6 (IL-6).13,14 Elevated plasma 
levels of CRP are not disease specific but are 
sensitive markers which are produced in response to 
tissue injury, infectious agents, and inflammation.12 
Various cross-sectional studies support the notion 
that CRP may be a marker for stroke and post-
stroke status.15,16 Several studies support the role of 
CRP in the prediction of ischaemic stroke risk and 
outcome, as well as the possible role of inflammation 
before and after stroke.17,18As the methods 
traditionally employed to measure CRP do not have 
good sensitivity, measurement of highly-sensitivity 
C-reactive protein (hsCRP) is recommended to 
evaluate atherothrombotic disease, which usually 
presents with lower CRP levels than the other 
inflammatory processes.14
Ginkgo biloba extract (EGb 761) is known to have 
neuroprotective properties in diseases associated 
with free radical generation. Extensive studies on 
G. biloba extracts showed their ability to protect 
brain neurons from oxidative stress19 and to inhibit 
apoptosis in cell culture.20  The G. biloba extracts 
that are currently used for medicinal purposes 
contain 24% flavonoid glycosides (quercetin, 
kaempferol, isorhamnetin) and 6% terpene lactones 
(ginkgolides A, B, C, M, J and bilobalides).21 The 
EGb 761 components eliminate free radicals 
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such as the hydroxyl radical and the superoxide 
anion.22 Quercetin is a powerful antioxidant in the 
flavonoid family due to its molecular configuration, 
which is capable of eliminating free radicals.23 
The pharmacologically active terpene lactones 
selectively inhibit the platelet-activating factor, 
preventing thrombus formation. Bilobalide is 
reported to possess neuroprotective properties.24
The aim of the present study was to investigate 
the presence of oxidative stress and inflammation 
in serum samples of ischaemic stroke patients by 
measuring MDA concentrations, total antioxidant 
status (TAS), and hsCRP in the early post-ischaemic 
period, and to determine the role of G. biloba 
therapy in correcting the markers of oxidative stress 
and inflammation in question. 
Methods
This double-blind randomised study was conducted 
in the Ibn Seena Hospital, Department of Neurology, 
in Mosul City, from January 2009 to April 2011. 
Approval was obtained from the ethical committee 
of the main health centre in Nineveh in Mosul City 
and the College of Medicine University of Mosul, 
Iraq. Our study included 31 CVA hypertensive 
patients (26 males and 5 females) suffering from 
ischaemic stroke, aged 69.03 ± 2.96 years and 30 
healthy control subjects aged 69.40 ± 2.69 years.
All patients included in this study were initially 
diagnosed as having CVA, or acute ischaemic 
stroke. All had problems with anterior circulation, 
a diagnosis made on the basis of full physical 
and neurological examinations by a neurologist. 
The diagnoses were then confirmed by either a 
magnetic resonance imaging (MRI) or computed 
tomography (CT) scan of the brain. Vascular risk 
factors including hypertension or diabetes mellitus, 
and smoking and alcohol habits were recorded. 
Patients with haemorrhagic stroke, intracranial 
tumour, or other neurological diseases, infection, 
inflammation, liver disease, and renal failure were 
excluded. For controls, the criteria were as follows: 
age ≥60 years, healthy subjects, non-smokers, and 
not taking vitamin supplements.
Ischaemic stroke patients were divided into two 
groups: group I (n = 15 of a possible 18 patients) 
included patients with ischaemic stroke who 
received conventional therapy (aspirin, rosuvastatin 
and lisinopril), and group II (n = 16 of a possible 
28 patients) included patients who received 
conventional therapy with G. biloba (1500 mg/
day) for 30 days. The dose was decided as a safe 
increment after previous promising results with 500 
and 1000 mg/day.
Blood samples were initially obtained from 
all CVA patients within 48–120 hours of their 
accidents, and before starting treatment. They were 
also taken from the controls. Assays of the serums 
MDA, TAS and hsCRP were done at the Department 
of Pharmacology in the College of Medicine at the 
University of Mosul. For the patient group, another 
blood sample was taken after treatment with either 
conventional therapy or conventional therapy with 
G. biloba, and the parameters reassessed.
MDA was measured by the method outlined 
by Buege and Aust where MDA reacts with 
thiobarbituric acid (TBA) to yield a red-coloured 
product.25 The absorbance of a 3 ml coloured layer 
was measured at 535 nm spectrophotometrically. 
TAS was measured by peroxidase/H2O2/ABTS 
colorimetric assay using commercial kits from 
Randox Laboratories, Belfast, UK. CRP was 
measured using the BioCheck hsCRP ELISA Kit 
(BioCheck, Inc., Foster City, California, USA).
Data were expressed as means ± standard 
deviation (SD). Statistical comparisons were 
performed using the Student’s t-test between 
patients before therapy and controls, and the one-
way analysis of variance (ANOVA). The Dunnett 
test was used to compare groups of patients. 
Linear regression analysis and Pearson correlation 
coefficients (r) were performed to determine the 
relationships between parameters. All statistical 
analyses were performed using the Statistical 
Package for the Social Sciences (SPSS) for Windows 
(Version 11.5, Chicago, Illinois, USA). A P value of 
Table 1: Concentrations of malondialdehyde (MDA), 
total antioxidant status (TAS), and highly-sensitivity 
C-reactive protein (hsCRP) in patients with acute 
ischaemic stroke before therapy and in healthy controls
Parameters Control(n = 30)
Ischaemic stroke 
patients
before therapy(n = 31)
MDA 
(µmol/L) 1.03 ± 0.17 2.11 ± 0.28***
TAS (mmol/L) 1.85 ± 0.12 1.06 ± 0.13***
hsCRP (mg/L) 0.53± 0.09 1.79 ± 0.18***
Notes: Results are expressed as mean ± SD; *** Significant difference 
from control at P ≤0.001
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<0.05 was considered statistically significant. 
Results
The serum levels of MDA, TAS and hsCRP from 
healthy subjects and patients with acute ischaemic 
stroke before starting drug therapy are shown in 
Table 1.  The serum levels of MDA and hsCRP were 
found to be significantly higher (P ≤0.001) and TAS 
were significantly lower in ischaemic stroke patients 
in the early post-ischaemic period (before starting 
therapy) in comparison to the controls [Table 1]. 
Table 2 shows the serum levels of MDA, TAS, 
and hsCRP in the two groups of ischaemic stroke 
patients before and after therapy. Patients in group 
I reported a significant reduction in serum levels 
of MDA (P ≤0.001) and hsCRP (P ≤0.01), and a 
significant increase (P ≤0.01) in serum levels of 
TAS after treatment with conventional therapy in 
comparison with their levels before therapy.
Also, patients in group II reported a significant 
reduction in serum levels of MDA (P ≤0.001) and 
hsCRP (P ≤0.001) and a significant increase in 
serum levels of TAS (P ≤0.001) after treatment with 
G. biloba together with conventional therapy in 
comparison with their levels before therapy.
By comparing the serum levels of MDA, TAS, 
and  hsCRP between the two groups of ischaemic 
stroke patients after therapy, no significant 
differences (P  = 0.19) were reported in serum MDA 
levels between group I, who received conventional 
therapy, and group II, who received G. biloba with 
conventional therapy, whereas the serum levels of 
TAS were found to be significantly higher (P ≤0.01) 
and hsCRP were significantly lower (P ≤0.01) in 
group II who received G. biloba with conventional 
therapy in comparison with group I who received 
conventional therapy alone [Table 2].
Regarding correlations between different 
biochemical parameters, Figures 1 to 3 show the 
relationships between MDA, TAS, and hsCRP in 
patients with acute ischaemic stroke. A significant 
negative correlation (r = -0.418, P = 0.001) was 
observed between MDA and TAS in the serum 
samples of patients with acute ischaemic stroke. 
MDA had a significant positive correlation with 
hsCRP (r = 0.729, P ≤0.001), and there was a 
significant negative correlation (r = -0.602, P = 
<0.001) between TAS and hsCRP in the serum 
samples of ischaemic stroke patients. 
Discussion 
There is strong indirect evidence that free radical 
production appears to be an important mechanism 
of brain injury after exposure to ischaemia 
and reperfusion.26 Free radicals in biological 
samples are difficult to measure because they 
are extremely reactive and have a short half-life. 
Therefore, particularly in human studies, indirect 
approaches have been used to demonstrate free 
radical production during cerebral ischaemia by 
measuring the products of free radical reaction 
with other molecules, such as lipids, proteins, and 
deoxyribonucleic acid (DNA), and the level or 
activity of antioxidant molecules.27,28 ROS causes 
impairment of cellular membrane stability and 
cell death by lipid peroxidation.29 MDA is the end 
product of the lipid peroxidation process.30 An 
increase in free radicals causes overproduction of 
MDA, which is commonly known as a marker of 
oxidative stress.31
Table 2: Concentrations of malondialdehyde (MDA), total antioxidant status (TAS), and highly-sensitivity C-reactive 
protein (hsCRP) in patients with acute ischaemic stroke before therapy and after therapy
Parameters
Group I (n = 15) Group II (n = 16)
Before therapy After conventional therapy Before therapy
After Ginkgo biloba+ 
conventional therapy 
(n = 16)
MDA (µmol/L) 2.12 ± 0.26 1.98 ± 0.24*** 2.10 ± 0.31 1.86 ± 0.23***
TAS (mmol/L) 1.07 ± 0.12 1.15 ± 0.12** 1.05 ± 0.14 1.31 ± 0.15*** δδ
hsCRP (mg/L) 1.80 ± 0.17 1.69 ± 0.20** 1.78 ± 0.19 1.42 ±0.24*** δδ
Notes: Results are expressed as mean ± SD; ** Significant difference compared to before therapy at P ≤0.01 and *** at P ≤ 0.001; δδ Significant 
difference compared to after conventional therapy at P ≤0.01
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In the present study, it was observed that 
ischaemic stroke patients in the early post- 
ischaemic period (before starting therapy) had 
significantly higher levels of serum MDA and 
hsCRP, and significantly lower TAS than controls. 
These findings provide evidence for the presence 
of oxidative stress and inflammation in ischaemic 
stroke patients.
There are several possible reasons for increased 
lipid peroxidation in cases of ischaemic stroke. 
First, the brain’s cellular membranes are very rich 
in polyunsaturated fatty acid side chains, which 
are especially sensitive to free radical attack. 
Additionally, they have a low content of antioxidant 
enzymes, such as catalase and glutathione 
peroxidase, while the brain contains a significant 
amount of iron, despite the fact that its iron binding 
capacity is not very high. Iron ions are known to 
stimulate free radical generation.32,33 Lower TAS was 
accounted for by an increased use of endogenous 
antioxidants to fight free radicals and oxidative 
stress during ischaemic stroke.34 
Our findings are in accordance with several 
studies which have been done to evaluate 
oxidative stress, antioxidant status, and markers of 
inflammation in ischaemic stroke patients.5-8 Most 
of these studies have shown enhanced levels of 
oxidative stress which are markers of inflammation, 
and reduced levels of antioxidants;5,10 however, some 
studies have reported controversial and conflicting 
results with regard to the levels of antioxidant 
enzymes.35
Studies evaluating markers of oxidative stress 
in patients in the early period of ischaemic stroke 
revealed an increase in the blood, cerebrospinal 
fluid, or salivary concentrations of lipid peroxides, 
protein carbonyl, homocysteine, nitric oxide, 
and of MDA, conjugated dienes, and other TBA-
reactive molecules at the onset of stroke.8,10,33,36–39 
Some studies showed persistently elevated MDA 
concentrations 6 months after strokes.40
Evaluations of antioxidants in blood, urine, or 
cerebrospinal fluid of ischaemic stroke patients 
revealed lower plasma vitamin C, E, vitamin 
A, and uric acid, lower glutathione peroxidase 
(GPX) activity, decreased glutathione (GSH) 
concentration, and a decreased total plasma 
antioxidant capacity.8,10,32,34,35,37,41
Data associated with superoxide dismutase 
(SOD) activity after acute ischaemic stroke are 
controversial. SOD activity of patients with acute 
ischaemic stroke was reported to be reduced in 
the serum and increased in the cerebrospinal 
fluid (CSF), increased in both CSF and serum, or 
remained unchanged.32,24,43
Several prospective studies have shown that 
an elevated serum CRP concentration is a strong 
predictor of cardiovascular events, including 
stroke. CRP plays an important role as a marker of 
outcome and may determine the degree of recovery 
for stroke patients.
In their study, Sánchez-Moreno et al. found 



















Figure 1: The relationship between malondialdehyde (MDA) and total antioxidant status (TAS) in patients with acute 
ischaemic stroke (r = -0.418, P = 0.001)
Oxidative Stress and C-Reactive Protein in Patients with Cerebrovascular Accident (Ischaemic Stroke) 
The role of Ginkgo biloba extract
202 | SQU Medical Journal, May 2012, Volume 12, Issue 2
elevated markers of inflammation, marked by CRP, 
intracellular adhesion molecule-1 (ICAM-1), and 
chemokine monocyte chemottractant protein-1 
(MCP-1), and that elevated CRP concentrations 
were associated with a two-fold increase in the 
risk of ischaemic stroke. Winbeck et al. observed 
that an increase in CRP levels between 12 and 24 
hours after the onset of symptoms predicts an 
unfavorable outcome and is associated with an 
increase in the incidence of cerebrovascular events. 
Mishra et al. observed an increase in hsCRP levels 
in stroke patients and that the increased levels were 
correlated with larger infarct, severe neurological 
deficit, and worse outcomes.12
Our study showed a highly significant negative 
correlation between serum MDA levels and TAS in 
ischaemic stroke patients, which suggests increased 
utilisation by ROS as an important contributing 
factor to the lower concentrations of antioxidants 
in ischaemic stroke patients. 
In the present study, we have investigated the 
relationship between markers of oxidative stress 
and markers of inflammation in ischaemic stroke 
patients. Ischaemic stroke patients with higher 
serum hsCRP concentrations, indicative of greater 
inflammatory response, also had higher serum 
MDA levels and lower TAS than those with lower 
serum hsCRP concentrations. This can be observed 
in the figures, which show that serum hsCRP levels 
positively correlate with lipid peroxidation products 
and negatively correlate with TAS. 
Our findings are in accordance with Sánchez-
Moreno et al.’s results in which they found that 
CRP were inversely associated with concentrations 
of antioxidant vitamins C and E, and positively 
associated with markers of oxidative stress 
(8-isoprostanes).41  
This study also showed that patients in groups 
I and II reported a significant reduction in serum 
levels of MDA and hsCRP and a significant 
increase in serum levels of TAS after treatment in 
comparison with their levels before therapy.
Interestingly, we did not observe any statistically 
significant differences in serum MDA levels between 
group I, who received conventional therapy, and 
group II, who received G. biloba with conventional 
therapy. In fact, the serum levels of TAS were found 
to be significantly higher, while those of hsCRP 
were significantly lower in group II who received 
G. biloba with conventional therapy, in comparison 
with group I who received conventional therapy 
alone.
Higher TAS in the serum of ischaemic stroke 
patients who received G. biloba together with 
conventional therapy (group II) was most likely 
caused by a lower use of endogenous antioxidants 
because of supplementary antioxidant effects of 
flavonoids glycosides.23.
Antioxidant treatment may be an efficient 
therapeutic option for cardiac embolisms and 
macroangiopathic strokes, contributing to an 
improvement of neurological deficits and the 
functional status of the patients through the 



















Figure 2: The relationship between malondialdehyde (MDA) and highly-sensitivity C-reactive protein (hsCRP) in 
patients with acute ischaemic stroke (r = 0.729, P = <0.001)
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and/or reperfusion.48 
It has been reported in many studies that 
G. biloba improved tissue damage in various 
organs through its antioxidant effect. Zeybek et 
al. reported that G. biloba significantly decreased 
MDA levels and histopathological scores of the 
pancreatitis in rats.49 Bridi et al. reported that G. 
biloba had antioxidant activity in the hippocampus, 
striatum, and substantia nigra of rats.50 EGb 761 has 
an antioxidant effect as a free radical scavenger, a 
relaxing effect on vascular walls, an ameliorating 
effect on blood flow and microcirculation, and a 
stimulating effect on neurotransmitters. Besides a 
direct scavenging effect on ROS, G. biloba exerts 
an anti-inflammatory effect on inflammatory cells 
by suppressing the production of ROS and nitrogen 
species.51
Several studies have shown that EGb 761 could 
protect cultured neurons against damage induced 
by peroxynitrate and hydrogen peroxide.19,51 Zhang 
et al. demonstrated that total ginkgolides (TG) 
(a terpenoid constituent of EGb 761) protected 
cultured rat cortical neurons from oxidative 
damages induced by hydrogen peroxide (H2O2).
52
EGb 761 extract, with free radical scavenging 
activity, has been shown to reduce the size of 
cerebral infarction and improve neurological 
behaviour in rats with permanent and transient 
mid-cerebral artery occlusion (MCAo).53,54
Saleem et al. showed that the standardised 
EGb761 significantly improved the outcome in mice 
after cerebral ischaemia and reperfusion in terms of 
neurobehavioral function and infarct size without 
affecting physiological parameters.55
Our findings suggest a potential role of G. 
biloba in acute ischaemic stroke, and the findings 
are important in view of the fact that stroke is, at 
present, the third leading cause of death worldwide.1 
The mechanisms by which G. biloba normalise  the 
cerebral damage, and reduce oxidative stress and 
inflammation, can probably be attributed to the 
antioxidant effects of flavonoids combined with 
the anti-inflammatory properties of the terpenoids 
bilobalide and ginkgolides A, B, C, M, J, and the 
terpenoids antagonists of platelet-activating factor 
(PAF), making this natural extract plausible to 
use in the treatment of ischaemic stroke, which 
is characterised by both oxidative damage and 
inflammation.56
One of the limitations of this study is that it does 
not relate the biochemical changes to the clinical 
evaluation and outcome prognosis.
Conclusion 
From this study, we conclude that acute ischaemic 
stroke is associated with oxidative stress and 
inflammatory response as indicated by increased 
lipid peroxidation products (MDA), reduced TAS 
and elevated levels of hsCRP in the early post-
ischaemic period, and that G. biloba therapy has 
a potential role in reducing oxidative damage and 

















Figure 3: The relationship between total antioxidant status (TAS) and highly-sensitivity C-reactive protein (hsCRP) in 
patients with acute ischaemic stroke (r = 0.602, P = <0.001)
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